Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 12/20 | 0.40 |
| ▸ | CA1 | P00915 | 12/20 | 0.40 |
| ▸ | CA2 | P00918 | 12/20 | 0.40 |
| ▸ | CA4 | P22748 | 5/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539552 | 0.88 | HTR6 (0.39) | HDAC3HDAC1HDAC2NCOR2LPAR1 | |
| SCHEMBL6539899 | 0.84 | RCE1 (0.42) | HDAC3HDAC1HDAC2NCOR2LPAR1 | |
| SCHEMBL6540329 | 0.84 | TAS2R14 (0.54) | HDAC1LPAR1LPAR5CA12CA1 | |
| SCHEMBL6676710 | 0.82 | POLB (0.47) | HDAC3HDAC1HDAC2NCOR2LPAR1 | |
| SCHEMBL6540837 | 0.82 | POLB (0.53) | HDAC3HDAC1HDAC2NCOR2CA12 | |
| SCHEMBL6540085 | 0.81 | ALDH1A1 (0.50) | LPAR1CA12CA1CA2CA4 | |
| SCHEMBL6540349 | 0.81 | HDAC1 (0.39) | HDAC3HDAC1HDAC2NCOR2LPAR1 | |
| SCHEMBL1799805 | 0.81 | HDAC1 (0.51) | HDAC3HDAC1HDAC2NCOR2LPAR1 | |
| SCHEMBL6540367 | 0.81 | HDAC3 (0.47) | HDAC3HDAC1HDAC2NCOR2LPAR1 | |
| SCHEMBL6802977 | 0.81 | CA12 (0.46) | HDAC3HDAC1HDAC2NCOR2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1389185-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094770-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | HDAC3 2501/4885HDAC1 1603/4885HDAC2 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.